Oncology-focused and clinical stage biotechnology company Kazia Therapeutics (ASX: KZA) has reported strong progress on the development of its lead drug candidates during the three months to 31 December.
Work focused on studies for brain cancer therapy paxalisib, particularly the international GBM AGILE study into glioblastoma driven by the Global Coalition for Adaptive Research.
The study already has several dozen sites running in the United States and opened to Canadian hospitals in November, with the first site being Sunnybrook Health Sciences Centre in Ontario.
Read more.
